Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and
chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus …

A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept
across 31 provinces in China and over 40 countries worldwide. The transition from first …

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the loss of
self-tolerance and formation of nuclear autoantigens and immune complexes resulting in …

The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …

In December, 2019, an outbreak of COVID-19 emerged in Wuhan, China and quickly spread
globally. As of May 7, 2020, there were 3 672 238 confirmed infections and 254 045 deaths …

Besides treating acute flares, the management of SLE should aim at preventing organ
damage accrual and drug-associated harms, improving health-related quality of life and …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

RA is known to be associated with an increased risk of serious infection. Even more than 50
years ago, observational studies showed a greater than 2-fold increased risk of serious …

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical,
emotional and socioeconomic consequences. Despite advances in targeted biologic and …

Infection is one of the leading causes of morbidity and mortality in systemic lupus
erythematosus (SLE). Bacterial infections are most frequent, followed by viral and fungal …